Experimental weight-loss drug retatrutide may help improve sleep apnea

A new weight-loss drug called retatrutide has shown significant promise in reducing obstructive sleep apnea symptoms in clinical trials, with up to 50% of participants improving to mild sleep apnea by the end of the study. The drug works as a triple hormone receptor agonist and appears to address sleep apnea primarily through weight loss rather than direct effects on breathing.